Quizartinib dihydrochloride is an oral, once-daily, highly potent and selective, type II tyrosine kinase inhibitor targeting FLT3 that has shown clinical activity in patients with FLT3-ITD-positive relapsed/refractory AML [5, 6]. The gene discussed is FLT3; the disease is acute myeloid leukemia.